Loading...
NPI 1346819992 · Houston, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ipseity Diagnostics LLC is a clinical medical laboratory provider located in Houston, Texas. This profile covers 10 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Ipseity Diagnostics LLC |
| Address | 2323 S Voss Rd Ste 240 |
| City | Houston |
| State | TX |
| ZIP | 77057 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 18, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $19.3M |
| Medicaid | $10.9K |
Business profile: IPSEITY DIAGNOSTICS LLC is classified as a Clinical Medical Laboratory and its billing mix is overwhelmingly driven by COVID-19 self-test provision services. The provider reported 1.6M claims for K1034 with $19.5M revenue on Medicare and 3.9K claims with $11.8K revenue on Medicaid, which indicates operational focus on high-volume COVID-19 test distribution rather than routine or broad-based diagnostic panels.
Revenue concentration (Medicare): The top three Medicare codes account for 99.6% of the provider’s total Medicare revenue, with K1034 alone representing $19.5M and 98.9% of Medicare revenue. This extreme concentration implies that virtually all Medicare earnings are tied to a single service line (K1034) rather than a diversified lab test portfolio.
Revenue concentration (Medicaid): Medicaid billing is effectively mono-coded: the top three Medicaid codes account for 100.0% of Medicaid revenue and K1034 constitutes 100.0% of the provider’s $10.9K Medicaid revenue. Medicaid activity therefore mirrors Medicare in code mix but is negligible in scale compared with the provider’s Medicare receipts.
Payer mix and scale: The provider’s lifetime Medicare revenue of $19.3M dwarfs its lifetime Medicaid revenue of $10.9K, indicating an almost exclusively Medicare-facing revenue profile at scale. In practical terms, IPSEITY DIAGNOSTICS operates as a Medicare-dominant billing entity with only trace Medicaid receipts tied to the same dominant COVID-19 test code.
Competitive standing for K1034: Nationally on Medicare, the provider ranks #18 of 30143 for K1034 (100th percentile) and is described as an extreme outlier, placing it far above typical national volume for this code. In-state for Medicaid, K1034 ranks #5 of 77 (95th percentile) and is noted as notably above typical state volume, confirming strong competitive prominence for this specific test product in both contexts.
Other service lines and niche testing: IPSEITY reports small but nonzero Medicare activity in genomic sequencing panels (examples include 81440 at $74.9K, 81443 at $55.2K, and 81419 at $40.8K), yet these codes collectively represent only a sliver of total Medicare revenue compared with K1034. National ranks for these genomic codes are modest to low (e.g., 81440 ranks #12 of 13, 8th percentile), indicating the provider is a limited participant in specialized genetic testing relative to peers.
Operational tenure: The provider’s NPI was enumerated on 2021-06-18 (~5 years ago), so this billing footprint—dominated by large-volume K1034 activity—has been established within roughly a five-year operating window. This relatively recent enumeration combined with outsized K1034 volumes suggests rapid scale-up in the COVID self-test provisioning line rather than a long-standing, diversified lab testing legacy.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,627,240 | $10 | $19.5M |
| 81440 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 100 mitochondrial genes encoded in the nucleus, including 19 specific… | 20 | $3,260 | $74.9K |
| 81443 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least 15 genes, such as the 20 gene examples listed in the code descriptor. The… | 20 | $2,400 | $55.2K |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 20 | $2,400 | $40.8K |
| 81448 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least five peripheral–neuropathy–related genes, such as the eight gene examples… | 20 | $570 | $13.2K |
| 81302 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the methyl CpG binding protein 2, or MECP2 gene. | 20 | $520 | $8.8K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 10 | $590 | $7.6K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 10 | $490 | $6.4K |
| 81330 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for sphingomyelin phosphodiesterase 1, acid lysosomal, also known as SMPD1. | 20 | $50 | $690 |
| 81332 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for serpin peptidase inhibitor, clade A, alpha–1 antiproteinase, antitrypsin, member 1, also known… | 20 | $40 | $650 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 3,940 | $1 | $11.8K |
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 5 | 80 | 340 | $1 | $1.5K |
Other providers in the same ZIP code as Ipseity Diagnostics LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Shelita Jones | TX | Family Nurse Practitioner | $6.7M | $0 |
| Christopher Tiangco | TX | Nurse Practitioner | $2M | $0 |
| Encompass Laboratory LLC | TX | Clinical Medical Laboratory | $1.1M | $5K |
| Tamara Liburd | TX | Occupational Therapist | $633.1K | $0 |
| Patricia Salvato | TX | Internal Medicine Physician | $608.7K | $0 |
| Andres Tapia | TX | Clinical Psychologist | $115K | $0 |
| Patricia Elles | TX | Certified Registered Nurse Anesthetist | $80.5K | $0 |
| Nicholas Defilippis | TX | Anesthesiology Physician | $24K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.